The reactivity to CK5/6 antibody in tumor cells from non-small cell lung cancers shed into pleural effusions predicts survival

Oncology Reports

Volumn 15, Issue 3, 2006, Pages 583-587

  Dejmek, Janna Sand ^a   Dejmek, Annika ^b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

CK5 6; Gender; Immunocytochemistry; Non small cell lung carcinoma; Pleural effusion; Survival

Indexed keywords

ANTIBODY; CYTOKERATIN 5; CYTOKERATIN 6; KERATIN; KRT5 PROTEIN, HUMAN; KRT6A PROTEIN, HUMAN; KRT6B PROTEIN, HUMAN; KRT6C PROTEIN, HUMAN; KRT6D PROTEIN, HUMAN; KRT6E PROTEIN, HUMAN;

AGED; ARTICLE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PLEURA EFFUSION; PREDICTION AND FORECASTING; PROGNOSIS; SURVIVAL;

AGED; AGED, 80 AND OVER; ANTIBODIES; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-5; KERATIN-6; KERATINS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PLEURAL EFFUSION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 33645750202     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.15.3.583     Document Type: Article

References (26)

1. Patel JD, Bach PB and Kris MG: Lung cancer in U.S. women - a contemporary epidemic. JAMA 291: 1763-1768, 2004. (Pubitemid 38489898)
2. Olak J and Colson Y: Gender difference in lung cancer: have we really come a long way, baby? J Thor Cardiovasc Disease 128: 346-351, 2004. (Pubitemid 39194686)
3. Sugiura S, Ando, Y, Minami H, Ando M, Sakai S and Shimokata K: Prognostic value of pleural effusion in patients with non-small cell lung cancer. Clin Cancer Res 3: 47-50, 1997. (Pubitemid 27079443)
4. Mott FE, Sharma N and Ashley P: Malignant pleural effusion in non-small cell lung cancer-time for a stage revision? Chest 119: 317-318, 2001. (Pubitemid 32150596)
5. Blobel GA, Moll R, Franke WW, Kayser KW and Gould VE: The intermediate filament cytoskeleton of malignant mesotheliomas and its diagnostic significance. Am J Pathol 121: 235-247, 1985. (Pubitemid 16230691)
6. Moll R: Molecular diversity of cytokeratins: significance for cell and tumor differentiation. Acta Histochem Suppl 41: 117-127, 1991.
7. Clover J, Oates J and Edwards C: Anti-cytokeratin 5/6. a positive marker for epithelial mesothelioma. Histopathology 31: 140-143, 1997. (Pubitemid 27357348)
8. Ordonez NG: Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma. Am J Surg Pathol 22: 1215-1221, 1998.
9. Ordonez NG: The immunohistochemical diagnosis of mesothelioma: a comparative study of epitheloid mesothelioma and lung adenocarcinoma. Am J Surg Pathol 27: 1031-1051, 2003.
10. Chu PG and Weiss LM: Keratin expression in human tissues and neoplasms. Histopathology 40: 403-439, 2002. (Pubitemid 34535443)
11. Fetsch PA and Abati A: Immunocytochemistry in effusion cytology. A contemporary review. Cancer (Cancer Cytopathol) 93: 293-308, 2001. (Pubitemid 32995213)
12. Dejmek A and Hjerpe A: The combination of CEA, EMA and BerEp4, and hyaluronan analysis specifically identifies 79% of all histologically verified mesotheliomas causing an effusion. Diagn Cytopathol 32: 160-166, 2005. (Pubitemid 40256266)
13. Silverman J: Effusion cytology of metastatic malignancy of unknown primary. Pathol Case Rev 6: 154-160, 2001.
14. Cury PM, Butcher DN, Fisher C, Corrin B and Nicholson AG: Value of the mesothelium-associated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura. Mod Pathol 13: 107-112, 2000. (Pubitemid 30109095)
15. Ramaekers FCS, Haag D, Kant A, Moesker O, Jap PH and Vooijs GP: Coexpression of keratin- and vimentin-type intermediate filaments in human metastatic carcinoma cells. Proc Natl Acad Sci USA 80: 2618-2622, 1983. (Pubitemid 13093360)
16. Berner HS, Davidson B, Berner A, et al: Expression of CD44 in effusions of patients diagnosed with serous ovarian carcinoma-diagnostic and prognostic implications. Clin Exp Metastasis18: 197-202, 2000. (Pubitemid 32165254)
17. Davidson B, Risberg B, Goldberg I, et al: Ets-1 mRNA expression in effusions of serous ovarian carcinoma patients is a marker of poor outcome. Am J Surg Pathol 25: 1493-1500, 2001. (Erratum in: Am J Surg Pathol 26: 539, 2002). (Pubitemid 33096963)
18. Davidson B, Risberg B, Reich R and Berner A: Effusion cytology in ovarian cancer: new molecular methods as aids to diagnosis and prognosis. Clin Lab Med 23: 729-754, 2003. (Pubitemid 37175552)
19. Gemma A, Takenaka K, Hosoya Y, et al: Altered expression of several genes in highly metastatic subpopulations of a human pulmonary adenocarcinoma cell line. Eur J Cancer 37: 1554-1561, 2001. (Pubitemid 32744688)
20. Leong AS: Pitfalls in diagnostic immunohistology. Adv Anat Pathol 11: 86-93, 2004.
21. Shidham VB, Lindholm PF, Kajdacsy-Balla A, Chang CC and Komorowsky R: Methods of cytologic smear preparation and fixation. Effect on the immunoreactivity of commonly used anticytokeratin antibody AE1/AE3. Acta Cytol 44: 1016-1022, 2000.
22. Watine J: Prognostic evaluation of primary non-small cell lung carcinoma patients using biological fluid variables. A systematic review. Scand J Clin Lab Invest 60: 259-273, 2000.
23. Cooper GM: The Cell - A Molecular Approach. 2nd edition. Sinauer Associates Inc., Sunderland, 2000.
24. Charalabopoulos K, Gogali A, Kostoula OK and Constantopoulos SH: Cadherin superfamily of adhesion molecules in primary lung cancer. Exp Oncol 26: 256-260, 2004.
25. Davidson B, Berner A, Nesland, et al: E-cadherin and alpha-, beta-, and gamma-catenin protein expression is up-regulated in ovarian carcinoma cells in serous effusions: J Pathol 192: 460-469, 2000.
26. Kim MA, Lee HS, Yang HK and Kim WH: Cytokeratin expression profile in gastric carcinomas. Hum Pathol 35: 576-581, 2004. (Pubitemid 38656942)